VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Neuroautoimmune disorders, such as multiple sclerosis and Guillain-Barre syndrome, have been documented in relation to various vaccines in the past. This paper uses passive reporting information from the CDC/FDA’s VAERS system to analyse whether neuroautoimmune presentations are reported at a relatively higher or lower rate, vis-a-vis other adverse effects, for COVID-19 vaccines than for other vaccines. Through computing the reporting odds ratios for a range of symptoms and comparator vaccines, a clear indication in favour of the safety of COVID-19 vaccines emerges, with reports of neuroautoimmune adverse events in relation to other adverse events being over 70% less likely for COVID-19 than for comparator vaccines ( ROR : 0.292, p < 0.0001). In comparison with other vaccines given as part of routine care in adulthood, COVID-19 vaccines have the lowest reporting odds ratio of neuroautoimmune adverse effects (median ROR : 0.246).
Article activity feed
-
SciScore for 10.1101/2021.06.13.21258851: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Except for male recipients of the COVID-19 vaccine, age distribution of neuroautoimmune disorders followed a bimodal pattern, peaking in the third and eight decades of life. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Categorisation of cases: Following ingestion using Python v. Pythonsuggested: (IPython, RRID:SCR_001658)Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Despite the limitations of this study, which drew on passive reporting data …
SciScore for 10.1101/2021.06.13.21258851: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Except for male recipients of the COVID-19 vaccine, age distribution of neuroautoimmune disorders followed a bimodal pattern, peaking in the third and eight decades of life. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Categorisation of cases: Following ingestion using Python v. Pythonsuggested: (IPython, RRID:SCR_001658)Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Despite the limitations of this study, which drew on passive reporting data with all its inherent problems, such as reporting bias and the lack of a reliable denominator, we have found evidence that supports the safety of COVID-19 vaccines with regard to neuroimmunological presentations. Statistical analysis indicated that in comparison to recipients of other vaccines, those who reported in respect of a COVID-19 vaccines were over 70% less likely to report a neuroimmunological presentation than a non-neuroimmunological presentation. Similarly, the number of reports fell significantly under what was expected in all but two somemwhat cohesive symptom groups: relapses of MS on one hand and autoimmmune encephalitis on the other. The fact that some forms of autoimmune encephalitis are distributed bimodally by age with a peak in the third and the seventh decade of life may support a hypothesis that the increase in cases of autoimmune encephalitis is the consequence of statistical noise and/or sampling bias due to the higher average age of COVID-19 vaccine recipients in the sample.[19] Similarly, multiple sclerosis exhibits a similar bimodality of age distribution, to the point that respective terms for early-onset (teens to early 30s) and late onset (50s and later) MS have become established in the literature.[20] Nevertheless, clinicians may, as a matter of abundance of caution, keep a closer eye on patients with known MS or risk factors for MS (such as previous diagnosis of optic...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-